THERAVANCE BIOPHARMA IRELAND LIMITED

Theravance Biopharma Ireland Limited is a research-driven biopharmaceutical company dedicated to transforming the treatment of specialty respiratory and neurologic diseases. By leveraging insight and innovation, the firm discovers, develops and commercialises what it terms "Medicines that Make a Difference®", aiming to improve the lives of patients and their caregivers.

The company's pipeline consists of internally discovered programmes that target significant unmet patient needs, with a particular focus on serious lung conditions. Its flagship product, YUPELRI® (revefenacin) inhalation solution, exemplifies Theravance's commitment to delivering novel, patient-centred therapies. An integrated team of scientists, clinicians and collaborators works together to bring these specialised medicines from the laboratory to the market.

Theravance Biopharma Ireland operates as a hub for creative problem-solvers and partners who share a passion for better solutions. Serving patients across Ireland and beyond, the organisation combines rigorous research with a patient-first ethos to advance the care of those living with complex respiratory and neurologic disorders.